107PPhase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study): Phase Ib results. (25th November 2018) - Kagawa, Y; Satake, H; Kato, T; Oba, K; Yasui, H; Nakamura, M; Watanabe, T; Hirata, K; Muro, K; Komatsu, Y; Yoshino, T; Yamazaki, K; et al.